INTERIM REPORT JANUARY-MARCH 2015
THE JANUARY-MARCH PERIOD 2015 IN BRIEF · Net sales amounted to MSEK 0.4 (6.4) · Net loss for the group was MSEK 15.3 (13.4) · Loss per share was SEK 0.02 (0.02) · Cash flow from operating activities was MSEK -19.4 (-13.1) · Cash and cash equivalents and other short-term investments at the end of the period totaled MSEK 32.2 (8.6) · Anders Lönner was appointed Executive Chairman of the Board and Maria Sjöberg CEO · A collaboration was initiated with the German pharmaceutical company Dr. Wolff SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD · The Board